Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

•Patients with advanced uterine leiomyosarcoma received trabectedin or dacarbazine.•Trabectedin significantly improved progression-free survival vs dacarbazine.•Lack of cumulative toxicity with trabectedin allows for prolonged treatment.